z-logo
Premium
Wilms' tumor 1 message and protein expression in bone marrow failure syndrome and acute leukemia
Author(s) -
Iwasaki Takashi,
Sugisaki Chiho,
Nagata Kohzo,
Takagi Kenji,
Takagi Akira,
Kojima Tetsuhito,
Ito Masafumi,
Nakamura Shigeo,
Naoe Tomoki,
Murate Takashi
Publication year - 2007
Publication title -
pathology international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.73
H-Index - 74
eISSN - 1440-1827
pISSN - 1320-5463
DOI - 10.1111/j.1440-1827.2007.02153.x
Subject(s) - immunostaining , wilms' tumor , leukemia , bone marrow , immunohistochemistry , pathology , myelodysplastic syndromes , fanconi anemia , refractory anemia , acute leukemia , medicine , cancer research , biology , gene , genetics , dna repair
Wilms' tumor 1 (WT1) is a useful marker for the diagnosis of acute leukemia and myelodysplastic syndromes (MDS). In the current study quantitative reverse transcription–polymerase chain reaction and immunostaining were used simultaneously to examine the relationship between WT1 RNA and protein level and also to evaluate WT1 as a tool to differentiate aplastic anemia (AA) and MDS refractory anemia (RA). Three types of WT1 messages (total, exon 5(+) and KTS(+)) and WT1 immunostaining of these diseases were analyzed. An increase of all three WT1 messages in high‐grade MDS and acute leukemia was observed as compared with the normal control, whereas there was no significant difference in WT1 message between AA and RA, suggesting that WT1 message is not a good tool to discriminate AA and RA. No significant difference was observed between normal and RA, except for exon 5 message. Three WT1 message levels had a significant correlation, suggesting that the total WT1 message is sufficient for clinical practice. Positive immunostaining of WT1 was observed only in the portion of acute leukemia and overt leukemia (OL) transformed from MDS with a high WT1 message level, suggesting the relatively high detection threshold of WT1 protein with the immunostaining method.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here